{
    "clinical_study": {
        "@rank": "158148", 
        "arm_group": [
            {
                "arm_group_label": "XEN Gel Stent", 
                "arm_group_type": "Other", 
                "description": "The XEN Gel Stent will be placed as a standalone procedure."
            }, 
            {
                "arm_group_label": "XEN Gel Stent with cataract surgery", 
                "arm_group_type": "Other", 
                "description": "The XEN Gel Stent with cataract surgery, only will occur if the patient is diagnosed with a cataract.."
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to evaluate the AqueSys XEN Implant for the treatment of\n      moderate primary open angle glaucoma patients when medications have failed to control\n      intraocular pressure (IOP). Effectiveness will be evaluated by comparing medicated\n      preoperative, intraocular pressure to postoperative values.  Additionally, the number of IOP\n      lowering medications subjects are on at each study visit will be compared to preoperative\n      medication."
        }, 
        "brief_title": "Evaluation of the XEN Implant in Moderate POAG Subjects", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Primary Open Angle Glaucoma", 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Open-Angle"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of primary open angle glaucoma\n\n          -  Subjects are taking at least one and no more than four IOP lowering medications.\n\n        Exclusion Criteria:\n\n          -  Angle Closure Glaucoma\n\n          -  Subject has neovascular, uveitic or angle recession glaucoma or any glaucoma\n             associated with vascular disorders\n\n          -  Clinically significant inflammation or infection in the study eye within 30 days\n             prior to the preoperative visit (e.g., blepharitis, conjunctivitis, keratitis,\n             uveitis, herpes simplex infection)\n\n          -  Presence of conjunctival scarring or prior conjunctival surgery or other conjunctival\n             pathologies (e.g., pterygium) in the target quadrant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02006693", 
            "org_study_id": "MS-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "XEN Gel Stent", 
                "description": "The XEN Gel Stent will be placed as a standalone procedure.", 
                "intervention_name": "XEN Gel Stent", 
                "intervention_type": "Device", 
                "other_name": [
                    "XEN Glaucoma Implant", 
                    "XEN Gel Stent", 
                    "ab interno"
                ]
            }, 
            {
                "arm_group_label": "XEN Gel Stent with cataract surgery", 
                "description": "Patient has been diagnosed with a cataract and has elected to have cataract surgery. The XEN Gel Stent will be placed along with cataract surgery.", 
                "intervention_name": "XEN Gel Stent with cataract surgery", 
                "intervention_type": "Device", 
                "other_name": [
                    "Cataract combo", 
                    "XEN Gel Stent", 
                    "XEN Glaucoma Implant", 
                    "ab interno"
                ]
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "XEN", 
            "Primary Open Angle Glaucoma", 
            "Filtration Device", 
            "Ab interno"
        ], 
        "lastchanged_date": "January 14, 2014", 
        "location": {
            "contact": {
                "email": "joerg.boecker@kk-bochcum.de", 
                "last_name": "Jorg Bocker, MD", 
                "phone": "492342993101"
            }, 
            "facility": {
                "address": {
                    "city": "Bochum", 
                    "country": "Germany", 
                    "zip": "44892"
                }, 
                "name": "University Eye Clinic Bochum-Langendreer"
            }, 
            "investigator": {
                "last_name": "Burkhard Dick, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "pgenge@aquesys.com", 
            "last_name": "Paul S Genge, BS", 
            "phone": "9494500250", 
            "phone_ext": "263"
        }, 
        "overall_official": {
            "affiliation": "AqueSys, Inc.", 
            "last_name": "Vanessa Vera, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "The number of IOP lowering medications compared to the number of preoperative IOP lowering medications.", 
                "safety_issue": "No", 
                "time_frame": "24 month visit"
            }, 
            {
                "measure": "The number of IOP lowering medications compared to the number of preoperative IOP lowering medications.", 
                "safety_issue": "No", 
                "time_frame": "12 month visit"
            }, 
            {
                "measure": "Comparing the intraocular pressure to the preoperative medicated intraocular pressure.", 
                "safety_issue": "No", 
                "time_frame": "24 month visit"
            }, 
            {
                "measure": "Comparing the intraocular pressure to the preoperative medicated intraocular pressure.", 
                "safety_issue": "No", 
                "time_frame": "12 month visit"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02006693"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "AqueSys, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AqueSys, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}